N 2 (187) 2024. P. 14–18

MORPHOLOGICAL CHANGES IN THE LIVER OF RATS OF BOTH SEXES WITH FRUCTOSE-INDUCED NONALCOHOLIC FATTY LIVER DISEASE

Ivan Horbachevsky Ternopil National Medical University of the Ministry of Health of Ukraine, Ternopil, Ukraine

DOI 10.32782/2226-2008-2024-2-2

The aim of study is to make a comparative analysis of structural changes in the liver rats of both sexes, which consumed 20% fructose solution instead of water for 2 months (after that they drank water for 2 months) and for 4 months.

Materials and methods: 72 white Wistar rats of both sexes were used in experiments. The age of the animals at the beginning of the research was 3.5–4 months. Rats were removed from of the experiment at the age of 7.5–8 months. The animals were divided into 3 groups: 1 – control, 2 – fructose-induced nonalcoholic fatty liver disease 2 months (after that they drank water for 2 months), 3 – fructose-induced nonalcoholic fatty liver disease 4 months. Fructose-induced nonalcoholic fatty liver disease in rats was induced by 20% fructose solution during 2 months (after that they drank water during 2 months) and 4 months. The development of nonalcoholic fatty liver disease was confirmed morphologically.

Results. Long-term use of a 20% fructose solution causes changes in lipid metabolism in the body of experimental animals, which is characterized by the development of fatty liver disease. Violation of the liver structure is more pronounced when consuming fructose for 4 months as compared to drinking fructose for 2 months with 2 months of rest. In female rats, compared to male ones, structural changes of the hepatic parenchyma (the volume of the affected areas and the degree of severity of changes in them) are significantly more evident in both terms of the study.

Key words: liver, nonalcoholic fatty liver disease, fructose, rats, sex, morphological changes.

BIBLIOGRAPHY

1. Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by fibroscan. Gastroenterol. Hepatol. 2022; 20(6): 143855. doi: 10.1016/j.cgh.2021.06.029.
2. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Rev. Gastroenterol. Hepatol. 2018; 15(7): 425–439. doi: 10.1038/s41575-018-0010-0.
3. Cong F, Zhu L, Deng L, Xue Q, Wang J. Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study. BMC Gastroenterol. 2023; 23(1): 90. doi: 10.1186/ s12876-023-02708-4.
4. El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Relationship between heart disease and liver disease: A two-way street. 2020; 9(3)567. doi: 10.3390/cells9030567.
5. Scalzo N, Canastar M, Lebovics E. Part 1: Disease of the Heart and Liver: A Relationship That Cuts Both Ways. Cardiol Rev. 2022; 30(3): 111–122. doi: 10.1097/CRD.0000000000000379.
6. Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015; 35(3): 270–290. doi: 10.1055/s-0035-1562947.
7. Targher G, Corey KE, Byrne CDJD. Metabolism. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction, and treatment. Diabetes Metabolsm. 2021; 47(2): 101215. doi: 10.1016/j.diabet.2020.101215.
8. Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE. 2013; 8(2): 57183. doi: 10.1371/journal.pone.0057183.
9. Geidl-Flueck B, Hochuli M, Németh Á et al. Fructose– and sucrose– but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. Hepatol. 2021; 75(1): 46–54. doi: 10.1016/j.jhep.2021.02.027.
10. Williams FR, Williams FR, Vallance A et al. Home-based exercise in patients awaiting liver transplantation: a feasibility study. Liver Transpl. 2019; 25(7): 995–1006. doi: 10.1002/lt.25442.
11. Turri-Silva N, Ricci-Vitor AL, Cipriano GJr et al. Functional resistance training superiority over conventional training in metabolic syndrome: A randomized clinical trial. Q. Exerc. Sport. 2020; 91(3): 415–424. doi: 10.1080/02701367.2019.1679333.
12. He B, Lu Z, He W, Huang B, Jiang H.Autonomic modulation by electrical stimulation of the parasympathetic nervous system:An emerging intervention for cardiovascular diseases. Ther. 2016; 34(3): 167–171. doi: 10.1111/1755-5922.12179.
13. Geidl-Flueck B, Hochuli M, Spinas GA, Gerber PA. Do Sugar-Sweetened Beverages Increase Fasting FGF21 Irrespective of the Type of Added Sugar? A Secondary Exploratory Analysis of a Randomized Controlled Trial. Nutrients. 2022; 14(19): 4169. doi: 10.3390/nu14194169.
14. Harrison SA, Ratziu V, Anstee QM et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024; 59(1): 51–63. doi: 10.1111/apt.17734.
15. Khodami B, Hatami B, Yari Z et al. Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial. Eur J Clin Nutr. 2022; 76(7): 987–994. doi: 10.1038/s41430-022-01081-x.
16. Kostiuk OA, Denefil OV, Holovata TK. Changes in biochemical parameters in the blood of high– and low-emotional rats with ethanol hepatosis. Medical and clinical chemistry. 2018; 20(3): 125–132. doi.org/10.11603/mcch.2410-681X.2018. v0.i3.9578 (in Ukrainian).
17. Horalskyi LP, Khomych VT, Kononskyi OI. Fundamentals of histological technique and morphofunctional research methods in normal and pathology: textbook. Zhytomyr: ZhNAEU, 2019: 286 p. (in Ukrainian).
18. Simons N, Veeraiah P, Simons PIHG et al. Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. Am J Clin Nutr. 2021; 113(2): 391–400. doi: 10.1093/ajcn/nqaa332.
19. Low WS, Cornfield T, Charlton CA, Tomlinson JW, Hodson L. Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding. Nutrients. 2018; 10(9): 1263. doi: 10.3390/nu10091263.